"FDA Investigates Potential Cancer Risk of CAR-T Therapy"

The FDA has found evidence suggesting that CAR T cell therapy, a groundbreaking cancer treatment, may increase the risk of secondary cancers and has instructed makers to include a warning about this risk in their labeling. Despite this, the FDA maintains that the benefits of CAR T therapy outweigh the potential risks. CAR T therapy, a form of immunotherapy, has shown remarkable response rates in treating specific blood cancers but is also known to have serious side effects, including the development of secondary cancers. While the exact possibility of this risk remains unclear, the FDA's investigation is ongoing, and the therapy continues to be used as a last-resort treatment for patients with high-risk cancers.